ReviewFrontiers in microbiology2016
Antibody Response to Mycoplasma pneumoniae: Protection of Host and Influence on Outbreaks?
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Prevalence, risk factors, and early prediction of refractory pneumonia caused by Mycoplasma pneumoniae in children: a systematic review and meta-analysis.European journal of pediatrics · 2026Pooled it
- Trial
- Bortezomib exhibited bacteriostatic activity and pro-inflammatory effect against Mycoplasma pneumoniae.The Journal of antibiotics · 2026Article
- An atypical F-type ATPase is necessary for the function of the antibody cleavage system MIB-MIP in mycoplasmas.PLoS pathogens · 2026Article
- In the shadow of COVID-19: changes in the seroprevalence of pediatric Mycoplasma pneumoniae.BMC infectious diseases · 2026Article
- Identification of Mycoplasma pneumoniae P1-interacting proteins by GST pull-down and analysis of its transcriptomic regulation in A549 cells.FEMS microbiology letters · 2026Article
- Nasal delivery ofMicrobiology spectrum · 2026Article
- Admission-time immunologic patterns in hospitalized children withFrontiers in pediatrics · 2026Article
- Comparative genomic analysis of Mycoplasma pneumoniae isolated in the United Kingdom, between 2016 and 2024.BMC genomics · 2025Article
- Attribution of causality in Stevens-Johnson syndrome/toxic epidermal necrolysis.The ocular surface · 2025Review
- Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Results From a Large French Observational Study (MyCOLD Study).American journal of hematology · 2025Observational
- A pathogen-detection's odyssey in a case of skull base osteomyelitis: Land ahoy!Annals of clinical microbiology and antimicrobials · 2025Article
- Development of human mycoplasma vaccines: navigating the IL-17A paradox.Frontiers in immunology · 2025Review
- Seroepidemiological survey ofFrontiers in pediatrics · 2025Article
- Reviewing advancement inFrontiers in microbiology · 2024Review
- Serum cytokine profiling reveals different immune response patterns during general and severeFrontiers in immunology · 2022Article
- Mycoplasma Pneumoniae Infection and Persistent Wheezing in Young Children: A Retrospective Case-Control Study.Frontiers in pediatrics · 2022Article
- Review
- Evaluation of the CARDS toxin and its fragment for the serodiagnosis of Mycoplasma pneumoniae infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Levels of pathogen virulence and host resistance both shape the antibody response to an emerging bacterial disease.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In humans of all ages, the cell wall-less and genome-reduced species Mycoplasma pneumoniae can cause infections of the upper and lower respiratory tract. The well-documented occurrence of major peaks in the incidence of community-acquired pneumonia cases reported world-wide, the multifaceted clinical manifestations of infection and the increasing number of resistant strains provide reasons for ongoing interest in the pathogenesis of mycoplasmal disease. The results of recent studies have provided insights into the interaction of the limited virulence factors of the bacterium with its host. In addition, the availability of complete M. pneumoniae genomes from patient isolates and the development of proteomic methods for investigation of mycoplasmas have not only allowed characterization of sequence divergences between strains but have also shown the importance of proteins and protein parts for induction of the immune reaction after infection. This review focuses on selected aspects of the humoral host immune response as a factor that might influence the clinical course of infections, subsequent protection in cases of re-infections and changes of epidemiological pattern of infections. The characterization of antibodies directed to defined antigens and approaches to promote their induction in the respiratory mucosa are also preconditions for the development of a vaccine to protect risk populations from severe disease due to M. pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.